<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03690544</url>
  </required_header>
  <id_info>
    <org_study_id>18-002914</org_study_id>
    <nct_id>NCT03690544</nct_id>
  </id_info>
  <brief_title>Apremilast for RAS</brief_title>
  <official_title>A Pilot Study Evaluating the Efficacy of Apremilast in the Treatment of Subjects With Severe Recurrent Aphthous Stomatitis (RAS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Celgene</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Determination of treatment efficacy and safety of Apremilast in patients with RAS&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will be a pilot study using apremilast 30mg orally twice daily, for treatment of&#xD;
      RAS in males and females between 18 and 70 years old.&#xD;
&#xD;
      Subjects will be recruited from the clinical practice of the Department of Dermatology or&#xD;
      Division of Rheumatology at Mayo Clinic Florida. Fifteen males and females with RAS will be&#xD;
      enrolled.&#xD;
&#xD;
      The study will consist of 3 phases: a screening phase, a 16 week treatment phase and an 8&#xD;
      week posttreatment observational follow-up phase.&#xD;
&#xD;
      The screening phase will consist of: obtaining informed consent, demographic information,&#xD;
      medical history, inclusion and exclusion criteria, prior and concomitant medication use,&#xD;
      adverse events; collecting vital signs and weight; performing complete physical examination&#xD;
      and limited physical examination; obtaining hematology, serum chemistry, urinalysis,&#xD;
      pregnancy test and providing contraception education.&#xD;
&#xD;
      During the 16-week treatment phase, all subjects receive apremilast.&#xD;
&#xD;
      All subjects who complete the active treatment phase are to enter the 8-week posttreatment&#xD;
      observational follow-up phase.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">October 12, 2018</start_date>
  <completion_date type="Anticipated">February 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">February 1, 2022</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Apremilast 30mg orally twice daily for 16 weeks</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Improvement in duration of RAS lesions</measure>
    <time_frame>up to 24 weeks</time_frame>
    <description>Improvement in the duration of oral ulcers will be used to factor the improvement of RAS lesions.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage change in number of RAS lesions</measure>
    <time_frame>up to 24 weeks</time_frame>
    <description>The percentage change in the number of oral ulcers will be used to factor the improvement of RAS lesions.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Improvement in duration of the remission period between ulcer episodes</measure>
    <time_frame>up to 24 weeks</time_frame>
    <description>Improvement in duration of the remission period between ulcer episodes will be used to factor the improvement of RAS lesions.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants with treatment-related adverse events as assessed by CTCAE v4.0</measure>
    <time_frame>24 weeks</time_frame>
    <description>Type, frequency, severity and relationship of the adverse events to apremilast will be assessed and reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Discontinuation of study participants</measure>
    <time_frame>24 weeks</time_frame>
    <description>Number of sbjects who prematurely discontinue treatment with apremilast due to any adverse event.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of clinically significant changes in vital signs and/or laboratory findings</measure>
    <time_frame>24 weeks</time_frame>
    <description>The frequency of clinically significant changes in vital signs and/or laboratory findings will be measured through a complete physical examination using physiological parameters, as well as hematology and serum chemistry.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Recurrent Aphthous Stomatitis</condition>
  <arm_group>
    <arm_group_label>Single Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Apremilast 30mg orally twice daily for 16 weeks, sixteen weeks on active study. Post treatment follow-up period of 8 weeks, in the Treatment of Subjects with Severe Recurrent Aphthous Stomatitis (RAS)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Apremilast 30mg</intervention_name>
    <description>Apremilast is an oral small-molecule inhibitor of phosphodiesterase (PDE) 4 that works intracellularly to modulate a network of pro-inflammatory and anti-inflammatory mediators. PDE 4 is a cyclic adenosine monophosphate (cAMP)-specific PDE and the dominant PDE in inflammatory cells. PDE4 inhibition elevates intracellular cAMP levels, which in turn down-regulates the inflammatory response by modulating the expression of TNF-alfa, IL-23, IL-17 and other inflammatory cytokines. Cyclic AMP also modulates levels of anti-inflammatory cytokines such as IL-10. Apremilast has immunomodulatory activity and, therefore, has the potential to be effective in the treatment of RAS.</description>
    <arm_group_label>Single Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
          1. Male and female subjects between 18 and 70 years of age&#xD;
&#xD;
          2. Oral ulcers that occurred at least monthly in the 6 month period prior to enrollment&#xD;
&#xD;
          3. Had at least 2 oral ulcers in the 4 weeks prior to enrollment at baseline&#xD;
&#xD;
          4. At least 3 oral ulcers during an ulcer flare&#xD;
&#xD;
          5. Patients must be candidates for systemic therapy for the treatment of oral ulcers,&#xD;
             those that are considered unsuitable for topical therapy alone based on severity of&#xD;
             disease, or whose oral ulcers cannot be adequately controlled with topical therapy.&#xD;
&#xD;
          6. Female premenopausal subjects must use one of the approved contraceptive options while&#xD;
             taking apremilast and for at least 28 days after administration of the last dose of&#xD;
             apremilast&#xD;
&#xD;
          7. Patients are able and willing to provide written informed consent after the nature of&#xD;
             the study is fully explained.&#xD;
&#xD;
          8. No evidence of systemic disease&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          1. Prior use of apremilast.&#xD;
&#xD;
          2. Use of any investigational drug within 4 weeks prior to randomization, or 5&#xD;
             pharmacokinetic/pharmacodynamic half-lives, if known (whichever is longer).&#xD;
&#xD;
          3. Having received concomitant immune modulating therapy 12 weeks prior to enrollment,&#xD;
             systemic steroids 6 weeks prior to enrollment or topical steroids within 4 weeks prior&#xD;
             to enrollment.&#xD;
&#xD;
          4. Pregnant women or breast-feeding mothers.&#xD;
&#xD;
          5. Systemic or opportunistic fungal infection.&#xD;
&#xD;
          6. Known active current or history of recurrent bacterial, viral, fungal, mycobacterial&#xD;
             or other infections (tuberculosis and atypical mycobacterial disease, hepatitis B and&#xD;
             C and herpes zoster, histoplasmosis, coccidiomycosis) or any major episode of&#xD;
             infection requiring hospitalization or treatment with IV or oral antibiotics within 4&#xD;
             weeks of the screening phase.&#xD;
&#xD;
          7. History of positive test for, or any clinical suspicion of, human immunodeficiency&#xD;
             virus (HIV), or congenital or acquired immunodeficiency.&#xD;
&#xD;
          8. History of depression.&#xD;
&#xD;
          9. Malignancy or history of malignancy, except for:&#xD;
&#xD;
             a - treated (ie, cured) basal cell or squamous cell in situ skin carcinomas; b -&#xD;
             treated (ie, cured) cervical intraepithelial neoplasia (CIN) or carcinoma in situ of&#xD;
             cervix with no evidence of recurrence within the previous 5 years.&#xD;
&#xD;
         10. Other than disease under study, any clinically significant (as determined by the&#xD;
             Investigator) cardiac, endocrinologic, pulmonary, neurologic, psychiatric, hepatic,&#xD;
             renal, hematologic, immunologic disease, or other major disease that is currently&#xD;
             uncontrolled.&#xD;
&#xD;
         11. Any condition, including the presence of laboratory abnormalities, which would place&#xD;
             the subject at unacceptable risk if he/she were to participate in the study.&#xD;
&#xD;
         12. Prior history of suicide attempt at any time in the subject's life time prior to&#xD;
             screening or randomization, or major psychiatric illness requiring hospitalization&#xD;
             within the last 3 years.&#xD;
&#xD;
         13. Active substance abuse or a history of substance abuse within 6 months prior to&#xD;
             screening.&#xD;
&#xD;
         14. Presence of any of the following vitamin deficiencies - B1, B2, B6, B12, vitamin C,&#xD;
             zinc, folate, iron.&#xD;
&#xD;
         15. Celiac disease.&#xD;
&#xD;
         16. Inflammatory Bowel Disease.&#xD;
&#xD;
         17. Genital aphthous ulcers.&#xD;
&#xD;
         18. Beh√ßet's disease.&#xD;
&#xD;
         19. History of positive patch test for allergic contact stomatitis.&#xD;
&#xD;
         20. Positive anti-endomysial or anti-gliadin antibodies.&#xD;
&#xD;
         21. A diagnosis of uveitis (current or previous).&#xD;
&#xD;
         22. Erythema nodosum-like lesions (current or previous).&#xD;
&#xD;
         23. An established diagnosis of a systemic disease (SLE, Reiter's, Sweet's and MAGIC&#xD;
             syndrome).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alison J Bruce</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic in Florida</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.mayo.edu/research/clinical-trials</url>
    <description>Mayo Clinic Clinical Trials</description>
  </link>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 4, 2018</study_first_submitted>
  <study_first_submitted_qc>September 27, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 1, 2018</study_first_posted>
  <last_update_submitted>September 29, 2021</last_update_submitted>
  <last_update_submitted_qc>September 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Alison J. Bruce</investigator_full_name>
    <investigator_title>Principle Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomatitis</mesh_term>
    <mesh_term>Stomatitis, Aphthous</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Apremilast</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

